Showing 1-10 of about 4848 articles.
Bragar Eagel & Squire
NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Sotheby’s (NYSE: BID) on behalf of Sotheby’s...
Progenics Pharmaceuticals Inc.
NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Bragar Eagel & Squire
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of NRC Group Holdings Corp. (NYSE: NRCG) on behalf of...
Bragar Eagel & Squire
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Caesars Entertainment Corporation (NASDAQ: CZR) on...
Bragar Eagel & Squire
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Shore Community Bank (Other OTC: SHRC) on behalf of...
Bragar Eagel & Squire
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Del Frisco’s Restaurant Group, Inc. (NASDAQ: DFRG) on...
Bragar Eagel & Squire
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of PCM, Inc. (NASDAQ: PCMI) on behalf of PCM shareholders...
Progenics Pharmaceuticals Inc.
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Inc.
Board has Positioned Progenics to Maximize Value as a Result of Proactive and Deliberate Strategy Velan’s Baseless Criticisms about the Development of AZEDRA and 1095 Reveal a Fundamental Lack of...
Kymab Group Ltd
Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies LifeArc will make a US$30 million equity investment in KymabLifeArc to gain access to...
Showing 1-10 of about 4848 articles.
